KR20150135743A - Composition comprising the extract of seaweed for wound healing and regenerating skin - Google Patents

Abstract

Compounds isolated from the fraction of hexane of the organic solvent fraction and the extract of the rocky mustache of the seaweed extract, the seaweed extract, and the extract of the seaweed extract according to the present invention are effective for cell proliferation and cell migration, .

Description

TECHNICAL FIELD The present invention relates to a composition for wound healing and skin regeneration comprising a seaweed extract,

The present invention relates to compositions for wound healing and skin regeneration comprising algae extract.

The skin occupies most of the human body and has various functions such as body temperature control, secretion, excretion, absorption, and especially functions to protect the human body physically, chemically and biologically from outside by being present at the outermost part of the human body. The skin is composed of epidermis, dermis and subcutaneous fat. The epidermis protects from the outside and inside of the body. The dermis has the function of supporting elasticity and support of skin, and subcutaneous fat has the function of maintaining body temperature.

Skin wounds usually indicate a state of damage to the epidermis and lower dermis layers that make up the skin. The normal course of wound healing is through the stages of hemostasis (clot formation), inflammation, proliferation (re-epithelialization, angiogenesis, fiber proliferation), and wound contraction. The hemostasis phase is the stage in which hematocrit is formed by red blood cells, white blood cells, platelets present in the blood vessels due to the rupture of the capillary vessels on the upper surface of the damaged window, and the immune cells such as white blood cells and neutrophils start to move to the wound sites And various cytokines are secreted. The inflammation stage is the stage of body protection that causes immune reaction with immune cells such as leukocyte, neutrophil, etc. that have been transferred to the wound area and substances such as foreign substances and pathogens entering from outside the wound, and treatment of damaged tissues occurs. The proliferative phase is the stage where fibroblast migration and proliferation occurs and tissue proteins such as collagen and elastin are produced and new blood vessels multiply into damaged tissue. Finally, the contractile phase is the step of tightening the loose coupling between the newly synthesized tissue and the proliferated cells, thereby increasing the joint strength and resilience of the tissue. In wound healing, rapid regeneration and restoration of the skin should be performed, and the proliferation phase must be performed promptly. In wound healing, fibroblasts migrate to the wound area, contracting the growth and wound area, and playing an important role in synthesizing extracellular matrix such as collagen.

Currently, EGF (epidermal growth factor), which is widely used as a wound healing agent because of its various activities, is either obtained by purification or obtained by overexpression in bacteria. It takes a lot of time, money, and labor to obtain by direct purification. Also, the over-expression method in bacteria has a problem that the recovery yield is very low due to low amount of cells in the cell and protease of bacteria. In addition, there is a report that EGF has a low therapeutic effect on a chronic wound site, and there is a problem that the price is higher than the efficiency due to a short half-life due to temperature and protease, so development of a new wound treatment agent is urgent.

Korean Patent No. 10-1042712

It is an object of the present invention to provide a pharmaceutical composition for wound healing and skin regeneration comprising an algae extract as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for skin regeneration containing the algae extract as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for wound healing and skin regeneration comprising an organic solvent fraction prepared by further extracting algae extract with an organic solvent as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for skin regeneration containing the organic solvent fraction as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for wound healing and skin regeneration comprising gadoleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for skin regeneration comprising the above-mentioned valoleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention provides a pharmaceutical composition for wound healing and skin regeneration comprising seaweed extract as an active ingredient.

The seaweeds may be brown algae and include, but are not limited to, rock bees ( Myelophycus simplex ), rocks ( Leathesia difformis ), semilogy bolle term ( Colpomenia peregrine ), L ( Ishige okamurae , Colpomenia bullosa , Ishige foliacea, and the like.

The seaweeds may be collected, cultured, or marketed without restriction. For example, they may be collected by washing with water to remove foreign matter and salt, and then dried.

The rock beard ( Myelophycus simplex ) is a brown algae, brown or dark brown, with a needle-like shape, and several hairs are gathered to form a bundle, which inhabits the rocks in the intertidal zone.

The rocks ( Leathesia difformis ) are brown algae. They grow in the form of yellowish brown bubbles attached to rocks or other plants and live in the intertidal zone.

Colpomenia peregrine is brown algae, brown foam or ball-shaped pouch with smooth, thick wrinkles on its surface and inhabits in the intertidal zone.

The Ishige okamurae ) is a brown algae, dark brown, reddish , round , irregularly wired, bifurcated, with a population of rocks in the intertidal zone.

The long bull term ( Colpomenia bullosa ) is brown algae, brownish red pepper-shaped pouches, several bundles of bubble-like basalts , and inhabits in the midwifery.

Ishige foliacea is a brown algae, bifurcated several times in the form of a brown duckwheat and grows on rocks and is attached to the plant of the tile. It can be found mainly in rocks in the intertidal zone.

In the present specification, " algae extract "Myelophycus simplex), Rocky bankLeathesia difformis), Semi-finished Bolle (Colpomenia peregrine), LIshige okamurae), Long Flame TermColpomenia bullosa),Ishige foliacea), As long as they are obtained by extracting the active ingredient from the group consisting of For example, the resultant product is obtained by adding the above-mentioned algae into water or an organic solvent and eluting the active ingredient through means such as settling, stirring, pressing, or heating.

The present invention also includes a lyophilized product obtained by lyophilizing the liquid extract obtained as described above. It also includes a powder obtained by pulverizing such a lyophilizate. In addition, it contains all the extracted extracts regardless of the available means for extracting the active ingredient, including those extracted and then subjected to freeze-drying and the like.

Other examples include extracts obtained by conventional extraction methods such as extracting by hot water or room temperature, or extracts obtained by conventional extraction methods as described in Korean medicine or textbooks.

It also includes a fraction extract obtained through a Stass Otto extraction method or various column chromatography methods, which is a special extraction method for separating specific active compounds.

The algae extract according to the present invention may be prepared by a conventional extraction method such as an ultrasonic extraction method, a filtration method and a reflux extraction method. Preferably, the seaweed may be an extract of C ₁ to C ₄ lower alcohol or a mixed solvent thereof, more preferably an extract of C ₁ to C ₄ lower alcohol, and most preferably methanol or It may be an extract extracted with ethanol. For example, algae are immersed in 80% methanol and extracted at room temperature for 24 hours. The extract residue is then removed and concentrated under reduced pressure to obtain an extract.

The present invention provides a cosmetic composition for skin regeneration containing the algae extract as an active ingredient.

The present invention provides a pharmaceutical composition for wound healing and skin regeneration comprising an organic solvent fraction prepared by further extracting the above-mentioned algae extract with an organic solvent as an active ingredient.

The organic solvent may be selected from the group consisting of hexane, chloroform, ethyl acetate, butanol, and water, but is not limited thereto.

The present invention provides a cosmetic composition for skin regeneration containing the organic solvent fraction as an active ingredient.

The present invention provides a pharmaceutical composition for wound healing and skin regeneration comprising gadoleic acid or a pharmaceutically acceptable salt thereof isolated from the algae extract as an active ingredient.

The gadoleic acid is called a rock beard ( Myelophycus simplex ), rocks ( Leathesia difformis ), semilogy bolle term ( Colpomenia peregrine , L ( Ishige okamurae ), Long bull ( Colpomenia bullosa and Ishige foliacea, and may be separated from the seaweed fraction, particularly, but not exclusively, from the hexane fraction of the rock beard extract.

The rock beard extract may be an extract of C ₁ to C ₄ lower alcohol or a mixed solvent thereof, more preferably an extract of C ₁ to C ₄ lower alcohol, most preferably methanol or It may be an extract extracted with ethanol.

The present invention provides a cosmetic composition for skin regeneration comprising gadoleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The pharmaceutical composition according to the present invention may contain 0.001 to 10 parts by weight per 100 parts by weight of the total composition.

The pharmaceutical composition of the present invention may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.

The pharmaceutical composition of the present invention may be a non-aqueous solution, a suspending agent may be propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, or the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

The pharmaceutical dosage forms of the compositions of the present invention may also be used in the form of their pharmaceutically acceptable salts and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set. The salt is not particularly limited as long as it is pharmaceutically acceptable so long as it is pharmaceutically acceptable and includes, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, , Benzenesulfonic acid, toluenesulfonic acid, and naphthalenesulfonic acid.

The composition of the present invention may be administered parenterally or orally, and may be administered in one to several divided doses so as to be administered in an amount of 0.1 to 500 mg and 1 to 100 mg per kg of body weight per day. The dosage for a particular patient may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate, severity of disease, and the like.

The pharmaceutical compositions according to the present invention can be administered orally or parenterally in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations such as ointments and creams, suppositories, And may be formulated and used in any form suitable for pharmaceutical preparations.

The composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like by various routes such as parenteral, oral, etc. All the ways of administration can be expected, Rectal, rectal or intravenous, intramuscular, subcutaneous, intrauterine or intracerebroventricular injection.

The cosmetic composition according to the present invention may contain 0.001 to 10 parts by weight per 100 parts by weight of the total composition.

The cosmetic composition may be prepared by dissolving or dispersing at least one compound selected from the group consisting of a fatty substance, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Such as cosmetics or skin, such as fillers, sequestering agents, chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics And may contain adjuvants conventionally used in the scientific field. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.

The external form of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. It may be in any form suitable for topical application, for example, as a solution, a gel, a solid, a paste anhydrous product, an emulsion obtained by dispersing the oil phase in water, a suspension, a microemulsion, a microcapsule, In the form of a non-ionic follicle dispersing agent, or in the form of creams, skins, lotions, powders, ointments, sprays or conical sticks. These compositions may be prepared according to conventional methods in the art. The composition according to the invention may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition containing the active ingredient according to the present invention is not particularly limited in its formulation and may be, for example, softening lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, Cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil and body essence.

The cosmetic composition as described above may be applied to the skin, or may be applied to the inside of the skin using a micro needle or the like.

The concentration of the gadoleic acid or a pharmaceutically acceptable salt thereof according to the present invention may be 0.01 - 30 μg / mL.

In one embodiment of the present invention, NIH3T3 fibroblast proliferation activity of the algae extract was measured. As a result, the best cell regeneration effect was obtained from a rock beard extract. Six compounds were isolated from hexane fraction of rock beard, And cell migration efficiency. As a result, compound 2 (F2, MSHJ) showed excellent cell proliferation and cell migration effect.

In one embodiment of the present invention, it was confirmed that Compound No. 2 (F2, MSHJ) was gadoleic acid.

In an embodiment of the present invention, the toxicity of gallolysan through zebrafish was confirmed, and as a result, it was confirmed that no adverse effect was observed at a concentration of less than 50 μg / mL. Therefore, the doloradic acid according to the present invention has no toxicity and side effects and can be safely used for long-term use for therapeutic and prophylactic purposes.

In an embodiment of the present invention, the regeneration effects of tail and tail fins in the zebra fish larvae and adult states were measured. As a result, as shown in Figs. 9 and 10, EGF (epidermal growth factor factor and 25 μg / mL of valoleic acid, respectively.

In one embodiment of the present invention, skin regeneration effect was confirmed through rats, and as shown in Figs. 11 and 12, excellent skin regeneration effect was observed in gallic acid at a concentration of 25 μg / mL.

Since the organic solvent fraction and the hydrolyzed goat extract of the seaweed extract according to the present invention, which are obtained by further extracting the above algae extract with an organic solvent, are effective for cell proliferation and wound healing, It can be utilized as a composition.

Six kinds of algae extracts which are native to the coast of Jeju according to the present invention or The composition comprising the compound derived therefrom is characterized by a composition of In vitro There is a cell proliferation and cell migration effect on In vivo And thus can be utilized as a composition for wound healing and skin regeneration.

Figure 1 shows the cell proliferation effect of fibroblasts of EGF (epidermal growth factor); Control: negative control.
FIG. 2 is a graph showing cell proliferation effects on six kinds of fibroblasts of seaweed; Control: negative control, Leathesia difformis : rock fence , Colpomenia bullosa : long bull's term, Colpomenia peregrine : bone quality term, Myelophycus simplex : rock beard, Ishige okamurae : L, Ishige foliacea: neolpae.
FIG. 3 is a schematic diagram showing fractionation steps of the rock beard extract. FIG.
FIG. 4 is a graph showing cell proliferation effect on fibroblasts of the rock beard fraction; FIG. MSH: hexane fraction, MSC: chloroform fraction, MSE: ethyl acetate, MSW: water fraction, Control: negative control, EGF (epidermal growth factor, 0.05 μg / ml): positive control.
Figure 5 shows the cell proliferation effect on fibroblasts of six compounds (F1, F2 (MSHJ), F3, F4, F5 and F6) derived from the rock beard fraction; Control: negative control, EGF (epidermal growth factor, 0.05 μg / ml): positive control.
6 is a diagram showing the cell migration effect of the compound No. 2 (F2, MSHJ) derived from the rock beard fraction; Control: negative control, EGF (epidermal growth factor, 0.05 μg / ml): positive control.
7 is a structural formula of gadoleic acid derived from rock salt.
Fig. 8 shows the results of evaluating the toxicity of gadoleic acid derived from rock beard in zebrafish; Fig. Control: EGF (epidermal growth factor, 0.05 μg / ml): Positive control, 1 μg / ml: treated with 1 μg / ml of valoleic acid, 10 μg / Group, 25 μg / ml: treated with 25 μg / ml of valoleic acid, 50 μg / ml: treated with 50 μg / ml of valoleic acid.
Figure 9 shows the effect of tail regeneration in zebrafish larvae of gadoleic acid derived from rock beard; Control: EGF (epidermal growth factor, 0.05 μg / ml): Positive control, 1 μg / ml: treated with 1 μg / ml of valoleic acid, 10 μg / Group, 25 μg / ml: treated with 25 μg / ml of valoleic acid.
10 shows the effect of regeneration of the caudal fin in zebrafish adult of gadoleic acid derived from rock beard; Control: EGF (epidermal growth factor, 0.05 μg / ml): Positive control, 1 μg / ml: treated with 1 μg / ml of valoleic acid, 10 μg / Group, 25 μg / ml: treated with 25 μg / ml of valoleic acid.
Fig. 11 shows the effect of wound healing in SD (Spraque-Dawley) rats of gadoleic acid derived from rock beard; Control: EGF (epidermal growth factor, 0.05 μg / ml): positive control, 10 μg / ml: treated with 10 μg / ml of valoleic acid, 25 μg / group.
FIG. 12 is a histological analysis result of wound healing effect in a SD (Spraque-Dawley) rat of gadoleic acid derived from rock beard; FIG. Control: EGF (epidermal growth factor, 0.05 μg / ml): positive control, 10 μg / ml: treated with 10 μg / ml of valoleic acid, 25 μg / Group, black arrow: location of epithelial cells

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention, but the scope of the present invention is not limited to the following examples. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.

Example 1 Preparation of Seaweed Extract

Six species of seaweed, Rock Beard ( Myelophycus simplex ), rocks ( Leathesia difformis ), semilogy bolle term ( Colpomenia peregrine , L ( Ishige okamurae ), Long bull ( Colpomenia bullosa and Ishige foliacea were immersed in 80% methanol and extracted at room temperature for 24 hours. The extracts were then removed and concentrated under reduced pressure to obtain an extract. Each extract was dissolved in dimethyl sulfoxide (DMSO) (Sigma, USA) after dispensing and used in the experiment.

< Example  2> Evaluation of cell proliferation efficacy

In order to evaluate the cell proliferation effect, a skin fibroblast NIH3T3 cell line (Korean Cell Line Bank, Korea) was inoculated into DMEM (Dulbeccos modified Eagle's medium) containing 10% bovine serum and L-glutamine (Gibco-BRL, USA) at 37 ° C in a 5% CO ₂ incubator. The NIH3T3 cell line was dispensed into a 24-well plate at 5 × 10 ⁴ cells / ml, and after 16 hours, it was replaced with DMEM medium containing 1.5% bovine serum. Treatment of six seaweed extracts (0.001, 0.1, 1, 10, 25 μg / ml) with positive control group EGF (Epidermal growth factor) (0.05 μg / ml) Lt; / RTI &gt; Cell proliferation was assayed using MTT (3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) assays. 50 μl of MTT solution (2 mg / ml) was added to the cultured medium for 24 hours and reacted for 2 hours. After the supernatant was completely removed, DMSO was added to completely dissolve the precipitate, and the absorbance was measured at 540 nm.

As a result, as shown in FIG. 2, six kinds of algae extracts treated by concentration showed cell proliferation effect in medium bulbous period and rock beard extract, and the most prominent cell proliferation effect was observed in rock beard.

< Example  3> Purification and Separation of Seaweed Extract-Derived Compounds

&Lt; 3-1 > Organic solvent fraction

To purify and separate the compounds showing cell proliferation effect from the rock beard extract obtained from Example 1, an organic solvent fraction was carried out. Individual organic solvent fractions were obtained using hexane (MSH), chloroform (MSC), ethyl acetate (MSE), butanol and water (MSW) (FIG. 3) The best fractions were selected.

As a result, as shown in FIG. 4, the hexane fraction showed the best cell proliferation effect, and it was confirmed that the effect was superior to that of the extract before the separation.

<3-2> Purification and Separation of Compound

A total of six compounds were obtained by separating the rocky bean hexane fractions using high performance centrifugal partition chromatography (HPCPC), which is easy to purify pure materials in a fast and single process.

The cell proliferation effect of the obtained compound was measured in the same manner as in Example 2, and as a result, it was confirmed that the compound 2 (F2, MSHJ) had the best cell proliferation efficiency as shown in FIG.

< Example  4> Evaluation of cell migration efficacy

In order to measure the cell migration rate of compound No. 2 (F2, MSHJ) isolated from rock beard according to Example 3, migration assay was performed using fibroblast. After 24 hours, cells were plated on a 24-well plate and cultured at a density of 1 x 10 ⁵ cells / ml in a 24-well plate. When the cells were cultured at 90% or more, 24- Respectively. The cells were washed with Dulbecco's Phosphate Buffered Saline (Sigma, USA) to remove the cells that had fallen on the bottom of the 24-well plate due to scratching, and then replaced with DMEM medium containing 1.5% bovine serum. The cells were treated with EGF (50 ng / ml) as a positive control and Compound 2 (F2, MSHJ) (0.1, 1, 10, 25 μg / ml) as an experimental group and cultured for 24 hours.

As a result, it was confirmed that the compound No. 2 (F2, MSHJ) treated by concentration as shown in Fig. 6 increased the migration of fibroblasts at all treated concentrations.

< Example  5> Identification of compound structure

The structure of the second compound (F2, MSHJ) isolated from the rock beard was identified and found to be gadoleic acid. The dicarboxylic acid has a double bond at the ninth carbon, and the 11-trans-eicosenoic, 8-eicosenoic, 11-eicosenoic and 5-trans- - There is a structural difference from the 5-eicosenoic.

< Example  6> Toxicity Evaluation of Compounds

In order to confirm the toxicity of garlestan separated from rock beard, it was tested for toxicity using Zebrafish. The adult zebrafish was purchased and placed in a 3 L acrylic tank, maintained at 28.5 ° C, 14/10 hours, light / dark conditions, and fed for 3 weeks with feeding for 2 weeks. The embryos were used for experiments obtained from natural light scattering induced in the morning. The resulting embryos were collected and placed in a 6-well plate containing 950 μl of embryo culture medium with a pipette. Twenty embryos per well were placed in the wells, and the concentration of valoleic acid (1, 10, 25, 50 μg / ml) .

On average, zebrafish wakes up on the third day (3 dpf, day post-fertilization) of the fertilized zebrafish, and the survival rate of the zebrafish larvae survived on the third day after treatment with gadoletic acid Respectively.

As a result, it was confirmed that there was no side effect in the case of less than 50 μg / mL of valoleic acid compared with the control group treated with nothing (EGF) (50 ng / ml) as shown in FIG.

< Example  7> Evaluation of Tail Regeneration Efficiency of Compounds

Zebrafish larvae were used to investigate wound healing effects of garlestar acid isolated from rock beard. After the fertilization, 3 dpf larvae were treated with EGF-treated group (50 ng / ml) and carbolic acid (1, 10, 25 μg / ml) , The tail regeneration effect was measured for 4 days (7 dpf).

As a result, as shown in Fig. 9, tail regeneration was completely observed in the EGF treatment group and the 25 μg / ml treatment group of carbolic acid compared with the control group treated with nothing at 5 dpf.

< Example  8> Evaluation of regeneration efficacy of caudal fin of compound

The regeneration effect of cauliflower acid separated from rock beard on the caudal fin was confirmed by using the adult zebra fish. EGF-treated experimental group (50 ng / ml) and vehicle (1, 10, and 25 μg / ml) treated with adult male zebrafish were placed in a 3 L acrylic tank with no treatment Were divided into groups. After cutting a portion of the tail fin of the zebrafish, saline, EGF, and valoleceane were intramuscularly injected into each zebrafish group to confirm tail rejuvenation efficacy for one week.

As a result, as shown in Fig. 10, it was confirmed that the regeneration effect of caudal fin was similar to that of EGF treated at 25 μg / mL of valoleic acid.

< Example  9> Evaluation of wound healing efficacy of compound

SD (Spraque-Dawley) rat (Rat) was used for the in vivo experiment to confirm the wound healing effect of galloolentan isolated from rock beard. (50 ng / ml) treated with EGF (10 ng / ml) and carbolic acid (10, 25 μg / ml) were administered to the rats of 20 SD rats. ), And the experiment was conducted. On the 0, 2, 4, 6, and 8 days after the procedure, wound size and skin texture were obtained from the experimental animals, respectively.

As a result, when wound size was confirmed from day 2 to day 4 as shown in FIG. 11, it was confirmed that wound healing was significantly effective when 25 μg / ml of gadoletic acid was treated compared to the control group without any treatment. In addition, when the wound size from 2 days to 6 days was confirmed, it was confirmed that wound healing was effective in EGF treatment group and 25 μg / ml treatment group of gallolysan.

< Example  10> Histological analysis of wound healing efficacy of compounds

The 6-day-old rat skin tissue obtained from the experiment according to Example 9 was immediately fixed in 10% formalin, embedded in paraffin, and cut to a thickness of 6 μm and stained with Masson trichrome stain.

As shown in FIG. 12, the epithelial cells were not recovered in the control group without any treatment, and the epithelial cells were recovered to the level just before the epithelial cells met the EGF treatment group. However, in the experimental group treated with 25 μg / ml of valoleic acid, epithelial cells were found to meet each other and re-epitaxialization completely occurred.

All experimental results for the above example are shown as mean ± standard error (SE) values of three independent experiments or more, and the statistical significance test between the experimental groups was performed using the Tukey test method.

Claims (10)

A pharmaceutical composition for wound healing and skin regeneration comprising an algae extract as an active ingredient, wherein the algae are selected from the group consisting of Myelophycus simplex , Leathesia difformis , Colpomenia peregrine ), L ( Ishige okamurae ), the Long Flame Term ( Colpomenia bullosa , Ishige foliacea, and the like. The pharmaceutical composition for wound healing and skin regeneration according to claim 1, wherein the algae extract is extracted with a C ₁ to C ₄ lower alcohol or a mixed solvent thereof. The cosmetic composition for skin regeneration according to claim 1, which contains the algae extract as an active ingredient. A pharmaceutical composition for wound healing and skin regeneration comprising an organic solvent fraction prepared by extracting the seaweed extract according to any one of claims 1 to 2 with an organic solvent as an active ingredient. The pharmaceutical composition according to claim 4, wherein the organic solvent is selected from the group consisting of hexane, chloroform, ethyl acetate, butanol, and water. 5. The cosmetic composition for skin regeneration according to claim 4, wherein the organic solvent fraction is contained as an active ingredient. A pharmaceutical composition for wound healing and skin regeneration comprising gadoleic acid or a pharmaceutically acceptable salt thereof isolated from seaweed extract as an active ingredient, wherein said algae is at least one selected from the group consisting of Myelophycus simplex , Leathesia difformis , Colpomenia peregrine ), L ( Ishige okamurae ), the Long Flame Term ( Colpomenia bullosa , Ishige foliacea, and the like. The pharmaceutical composition according to claim 7, wherein the gadoleic acid is isolated from a hexane fraction of a rock beard extract. The pharmaceutical composition according to claim 8, wherein the rock beard extract is extracted with a C ₁ to C ₄ lower alcohol or a mixed solvent thereof. The cosmetic composition for skin regeneration according to claim 7, which contains gadoleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Images